Inviragen and SingVax have merged their vaccine development operations. Both companies are working on vaccines for infectious diseases that plague emerging countries. Inviragen has offices in Madison, WI and Fort Collins, CO, while SingVax is located in Singapore. To fund the newly merged entity, the new company raised $15 million in a Series A round from an international syndicate of investors. More details...